BBIO vs. OGN, APLS, MDGL, IONS, NUVL, ALPN, PRGO, ALKS, INSM, and BPMC
Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Perrigo (PRGO), Alkermes (ALKS), Insmed (INSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
BridgeBio Pharma (NASDAQ:BBIO) and Organon & Co. (NYSE:OGN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation.
In the previous week, BridgeBio Pharma had 10 more articles in the media than Organon & Co.. MarketBeat recorded 17 mentions for BridgeBio Pharma and 7 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.85 beat BridgeBio Pharma's score of 0.54 indicating that Organon & Co. is being referred to more favorably in the news media.
Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma received 124 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.63% of users gave BridgeBio Pharma an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 28.5% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 1.2% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Organon & Co. has a net margin of 16.50% compared to BridgeBio Pharma's net margin of -246.24%. BridgeBio Pharma's return on equity of 0.00% beat Organon & Co.'s return on equity.
BridgeBio Pharma has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
BridgeBio Pharma currently has a consensus price target of $48.00, suggesting a potential upside of 59.52%. Organon & Co. has a consensus price target of $22.60, suggesting a potential upside of 3.67%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe BridgeBio Pharma is more favorable than Organon & Co..
Summary
BridgeBio Pharma beats Organon & Co. on 12 of the 19 factors compared between the two stocks.
Get BridgeBio Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BridgeBio Pharma Competitors List
Related Companies and Tools
